速递｜七名董事会成员已辞职！诺和诺德基金会更换公司董事会，领导层内部分歧严重

Core Viewpoint - Novo Nordisk is undergoing a significant leadership transition driven by its largest shareholder, the Novo Foundation, aiming for more aggressive measures to revitalize the company amid recent challenges in the obesity and diabetes drug market [2][5]. Group 1: Leadership Changes - The board chairman Helge Lund and six other board members will resign, with former CEO Lars Rebien Sørensen returning to the CEO position for a term of two to three years [2][5]. - Sørensen emphasized the need for a new perspective and energy to support management in crucial transformation processes [4][5]. - The new board will support CEO Maziar Mike Doustdar, who has been pushing for a major restructuring that has led to thousands of job cuts and the closure of several research departments [4][5]. Group 2: Market Challenges - Novo Nordisk's stock has dropped 36% year-to-date, with a further decline of 1.4% following the announcement of board changes [4]. - Analysts have noted that the company has fallen behind competitors like Eli Lilly due to a slow response to changes in the U.S. market [5][6]. - Sørensen acknowledged that the board failed to recognize the importance of market changes in a timely manner, impacting the company's ability to adjust its strategy [8]. Group 3: Strategic Focus - The Novo Foundation expressed dissatisfaction with the previous board's speed and effectiveness in addressing the rapidly changing obesity and metabolic market [5][6]. - The new board will focus on members with consumer experience, as GLP-1 drugs are becoming more consumer-oriented [5][6]. - The leadership changes reflect a desire for Novo Nordisk to adopt a more proactive approach in the competitive obesity and diabetes treatment market [8].